Analysts Adjust Forecasts for Acadia Following Earnings Beat Acadia Pharmaceuticals exceeded earnings expectations for 2024, reporting a 95% higher-than-expected profit per share. However, analysts have lowered 2025 earnings per share estimates by 61%, citing potential challenges. Despite this, revenue forecasts remain steady, with a projected 11% growth. The stock's price target remains unchanged, reflecting investor confidence.23